Paeonol, an Ingredient of Kamishoyosan, Reduces Intracellular Lipid Accumulation by Inhibiting Glucocorticoid Receptor Activity in 3T3-L1 Cells.
3T3-L1 Cells
Acetophenones
/ pharmacology
Adipocytes
/ drug effects
Adipogenesis
/ drug effects
Animals
CCAAT-Enhancer-Binding Protein-delta
/ genetics
Drugs, Chinese Herbal
/ pharmacology
Dyslipidemias
/ metabolism
Hypolipidemic Agents
/ pharmacology
Mice
Receptors, Glucocorticoid
/ antagonists & inhibitors
Signal Transduction
Triglycerides
/ metabolism
C/EBP-δ
Kamishoyosan
Kampo medicine
Moutan cortex
adipocyte
glucocorticoid receptor
paeonol
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
24 Jan 2020
24 Jan 2020
Historique:
received:
26
12
2019
revised:
14
01
2020
accepted:
21
01
2020
entrez:
30
1
2020
pubmed:
30
1
2020
medline:
28
11
2020
Statut:
epublish
Résumé
Excessive triglyceride accumulation in lipid-metabolizing tissues is associated with an increased risk of a variety of metabolic diseases. Kamishoyosan (KSS) is a Kampo composed of 10 constituent herbs, and contains moutan cortex (MC) and paeonol (PN) as the major ingredient of MC. Here, we demonstrate the molecular mechanism underlying the effect of KSS on the differentiation of mouse preadipocytes (3T3-L1 cells). KSS inhibited the accumulation of triglycerides in a dose-dependent manner in 3T3-L1 cells that were induced to differentiate into adipocytes. We also found that MC and PN were responsible for the anti-adipogenetic effect of KSS and significantly suppressed the expression of CCAAT/enhancer-binding proteins-δ (C/EBP-δ) mRNA 3 days after the induction of differentiation. Thus, PN may contribute to the anti-adipogenetic property of MC in 3T3-L1 cells. In addition, PN inhibited dexamethasone (Dex)-induced glucocorticoid receptor (GR) promoter activity. Taken together, these results suggest that PN suppresses C/EBP-δ expression by inhibiting Dex-induced GR promoter activity at the early stage of differentiation and, consequently, delays differentiation into mature adipocytes. Our results suggest that the habitual intake of Kampo-containing PN contributes to the prevention of the onset of metabolic diseases by decreasing the excessive accumulation of triglycerides in lipid-metabolizing tissues.
Identifiants
pubmed: 31991567
pii: nu12020309
doi: 10.3390/nu12020309
pmc: PMC7071193
pii:
doi:
Substances chimiques
Acetophenones
0
Cebpd protein, mouse
0
Drugs, Chinese Herbal
0
Hypolipidemic Agents
0
Receptors, Glucocorticoid
0
Triglycerides
0
kamisyoyo san
0
CCAAT-Enhancer-Binding Protein-delta
142662-43-9
paeonol
3R834EPI82
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cell. 2017 Jul 13;170(2):340-351.e12
pubmed: 28709001
Nat Commun. 2013;4:2563
pubmed: 24113622
J Biol Chem. 1994 Jul 22;269(29):19041-7
pubmed: 8034662
Int Immunopharmacol. 2004 Oct;4(10-11):1353-65
pubmed: 15313433
Fertil Steril. 2010 Aug;94(3):1037-43
pubmed: 19476935
Diabetes Metab Syndr. 2015 Jan-Mar;9(1):46-50
pubmed: 25450819
Evid Based Complement Alternat Med. 2013;2013:413906
pubmed: 23762131
Int J Obes (Lond). 2006 Mar;30(3):520-7
pubmed: 16302014
Oncogene. 2011 Jul 21;30(29):3207-21
pubmed: 21423206
Mol Cell Biol. 2017 Jan 4;37(2):
pubmed: 27777311
Mol Cell Biol. 2014 Mar;34(6):939-54
pubmed: 24379442
Eur Heart J. 2016 Dec 21;37(48):3560-3568
pubmed: 26685971
J Pineal Res. 2009 Oct;47(3):221-7
pubmed: 19663997
Cytotechnology. 2010 Jul;62(3):245-55
pubmed: 20596890
Front Pharmacol. 2019 Mar 19;10:261
pubmed: 30941042
Arch Neurol. 2005 Oct;62(10):1556-60
pubmed: 16216938
J Cell Biochem. 2015 Jul;116(7):1195-204
pubmed: 25536154
Mol Cell Endocrinol. 2007 Sep 15;275(1-2):43-61
pubmed: 17624658
Tohoku J Exp Med. 2009 Sep;219(1):53-62
pubmed: 19713685
J Clin Psychiatry. 2005 Feb;66(2):248-52
pubmed: 15705012
Expert Opin Drug Saf. 2016;15(4):457-65
pubmed: 26789102
Maturitas. 2009 Feb 20;62(2):146-52
pubmed: 19179025
Phytother Res. 2012 Jan;26(1):91-100
pubmed: 21557367
PLoS One. 2015 Jul 28;10(7):e0134187
pubmed: 26218569
PLoS One. 2015 Jul 07;10(7):e0131165
pubmed: 26151135
Biomed Chromatogr. 2003 Dec;17(8):504-8
pubmed: 14648606
Front Pharmacol. 2015 Aug 28;6:176
pubmed: 26379550
J Biol Chem. 1983 Mar 25;258(6):3559-64
pubmed: 6833214
Nat Rev Endocrinol. 2014 Aug;10(8):455-465
pubmed: 24935119
Dev Cell. 2003 Jan;4(1):119-29
pubmed: 12530968
Prostate. 2018 Feb;78(3):222-232
pubmed: 29194690
EMBO J. 1997 Dec 15;16(24):7432-43
pubmed: 9405372
J Biol Chem. 1978 Oct 25;253(20):7570-8
pubmed: 81205
Integr Med Res. 2017 Dec;6(4):395-403
pubmed: 29296566
Evid Based Complement Alternat Med. 2017;2017:1052976
pubmed: 29234362
Evid Based Complement Alternat Med. 2015;2015:750345
pubmed: 26495024
Eur J Biochem. 2004 Oct;271(20):4042-52
pubmed: 15479233
J Biol Chem. 1996 May 3;271(18):10697-703
pubmed: 8631877
Front Nutr. 2018 Jul 23;5:66
pubmed: 30083536
Biosci Rep. 2015 Dec 16;36(1):e00287
pubmed: 26677203
BMJ. 2006 Sep 23;333(7569):640-2
pubmed: 16990325
Oral Dis. 2017 Oct;23(7):956-965
pubmed: 28513060